ARPA-H picks UpDoc, Tempus and Atman to build AI tools for heart disease
UpDoc, Tempus AI and Atman Health will participate in a new program that aims to build FDA-authorized agentic AI tools to care for people with heart disease, the federal government announced Wednesday. Called ADVOCATE, the ...
The U.S. government's Advanced Research Projects Agency for Health (ARPA-H) has allocated $62.7 million to develop AI-driven artificial intelligence (AI) bots to assist in treating heart failure, announced on Wednesday. This initiative, named ADVOCATE, aims to produce partially autonomous FDA-authorized AI devices capable of assessing symptom severity, prescribing medication, and ordering laboratory tests.
On the first day of the program, ARPA-H selected four health technology companies and research teams, including Atman Health, UpDoc, Tempus AI, Stanford University, Duke University, and Kaiser Permanente health system. ARPA-H may grant additional funds to other teams. The first-year funding of $33.7 million can be adjusted up or down.
In the U.S., approximately 6.7 million individuals suffer from heart failure, but optimal treatment is often hindered by the challenge of accessing specialists, particularly in rural and other underserved areas. The program's objective is to utilize AI agents developed under ARPA-H's guidance to bridge this gap in healthcare.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
